IRIDEX CORP(IRIX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-07-04.

IRIDEX CORP (IRIX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRIX at 25.0/100 on a 32-signal composite quality model, placing it at rank #2,679 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (9.0) and revenue scale (9.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IRIDEX CORP reports quarterly revenue of $12.6M, net income of $-1.3M, an operating margin of -8.2%. Top institutional holders of IRIX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, MORGAN STANLEY, based on the most recent SEC filings. IRIX trades on the Nasdaq exchange and files with the SEC under CIK 1006045. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRIDEX CORP directly from SEC EDGAR.